Hologic (HOLX) Tops Q2 EPS by 1c; Bumps Outlook

Hologic (NASDAQ: HOLX) reported Q2 EPS of $0.47, $0.01 better than the analyst estimate of $0.46. Revenue for the quarter came in at $693.3 million versus the consensus estimate of $687.41 million.

"We posted another good quarter, highlighted by 14.6% growth in non-GAAP EPS," said Steve MacMillan, the Company's Chairman, President and Chief Executive Officer. "The strength of our business model was evident at multiple levels in the quarter. Our U.S. businesses grew revenue at a double-digit rate, we improved both gross and operating margins while making significant investments in our future, and we aggressively redeployed capital, leading to EPS growth more than double the rate of sales."

GUIDANCE:

Hologic sees Q3 2016 EPS of $0.47-$0.48, versus the consensus of $0.48. Hologic sees Q3 2016 revenue of $695-705 million, versus the consensus of $717.02 million.

Hologic sees FY2016 EPS of $1.89-$1.91, versus prior guidance of $1.86-$1.90 and the consensus of $1.89. Hologic sees FY2016 revenue of $2.81-2.83 billion, versus prior guidance of $2.8-2.83 billion and the consensus of $2.83 billion.

For earnings history and earnings-related data on Hologic (HOLX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Reading (RDI) Tops Q2 EPS by 4c
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c